The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas.
Johnny Duerinck
No relevant relationships to disclose
Stephanie Du Four
No relevant relationships to disclose
An Van Binst
No relevant relationships to disclose
Hendrik Everaert
No relevant relationships to disclose
Alex Michotte
No relevant relationships to disclose
Jean D'haens
No relevant relationships to disclose
Bart Neyns
Research Funding - Pfizer